The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 145-155

  Cuesta, Marc ^a   Aungier, Juliet ^a   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Circadian; Huntington's disease; L DOPA; Methamphetamine; R6 2; Sleep

Indexed keywords

LEVODOPA; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINERGIC SYSTEM; CIRCADIAN OSCILLATOR; CIRCADIAN RHYTHM; CONTROLLED STUDY; DARKNESS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; HUNTINGTON CHOREA; LOW DRUG DOSE; MALE; METHAMPHETAMINE SENSITIVE CIRCADIAN OSCILLATOR; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REST; SUPRACHIASMATIC NUCLEUS; SURVIVAL RATE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; BIOLOGICAL CLOCKS; CENTRAL NERVOUS SYSTEM STIMULANTS; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; METHAMPHETAMINE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; SUPRACHIASMATIC NUCLEUS;

EID: 81955167992     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.07.016     Document Type: Article

References (69)

1. Anand A., Charney D.S. Norepinephrine dysfunction in depression. J. Clin. Psychiatry 2000, 10:16-24.
2. Anderson K.E., Gehl C.R., Marder K.S., Beglinger L.J., Paulsen J.S. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J. Nerv. Ment. Dis. 2010, 198:334-338. Huntington's Study Group.
3. Antonini A., Leenders K.L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., De Yebenez J.G., Boesiger P., Weindl A., Maguire R.P. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996, 119:2085-2095.
4. Aschoff J., Wever R. Human circadian rhythms: a multioscillator system. Fed. Proc. 1976, 35:2326-2332.
5. Aziz N.A., Anguelova G.V., Marinus J., Lammers G.J., Roos R.A. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat. Disord. 2010, 16:345-350.
6. Bates G.P., Harper P.S., Jones L. Huntington's disease, Ed3 2002, Oxford UP, Oxford.
7. Bode F.J., Stephan M., Wiehager S., Nguyen H.P., Björkqvist M., von Hörsten S., Bauer A., Petersén A. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model. Behav. Brain Res. 2009, 205:175-182.
8. Bruguerolle B., Simon N. Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin. Neuropharmacol. 2002, 25:194-201.
9. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
10. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:981-989.
11. Challet E., Malan A., Pévet P. Daily hypocaloric feedings entrains circadian rhythms of wheel-running and body temperature in rats kept in constant darkness. Neurosci. Lett. 1996, 211:1-4.
12. Challet E., Mendoza J., Dardente H., Pévet P. Neurogenetics of food anticipation. Eur. J. Neurosci. 2009, 30:1976-1987.
13. Ciamei A., Morton A.J. Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. Neurobiol. Learn. Mem. 2008, 89:533-544.
14. Costa e Silva J.A. Sleep disorders in psychiatry. Metabolism 2006, 55:S40-S44.
15. Duff K., Paulsen J., Mills J., Beglinger L.J., Moser D.J., Smith M.M., Langbehn D., Stout J., Queller S., Harrington D.L. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75:500-507. PREDICT-HD Investigators and Coordinators of the Huntington Study Group.
16. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 2000, 406:1-13.
17. Foltz C.J., Ullman-Cullere Guidelines for assessing the health and condition of mice. Lab. Anim. 1999, 28:28-32.
18. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120:503-514.
19. Hickey M.A., Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
20. Hofmann N. Understanding the neuropsychiatric symptoms of Huntington's disease. J. Neurosci. Nurs. 1999, 31:309-313.
21. Honma S., Honma K. Phase-dependent phase shift of methamphetamine-induced circadian rhythm by haloperidol in SCN-lesioned rats. Brain Res. 1995, 674:283-290.
22. Honma K., Honma S. The SCN-independent clocks, methamphetamine and food restriction. Eur. J. Neurosci. 2009, 30:1707-1717.
23. Honma K., Honma S., Hiroshige T. Disorganization of the rat activity rhythm by chronic treatment with methamphetamine. Physiol. Behav. 1986, 35:687-695.
24. Honma K., Honma S., Hiroshige T. Activity rhythms in the circadian domain appear in suprachiasmatic nuclei lesioned rats given methamphetamine. Physiol. Behav. 1987, 40:767-774.
25. Honma S., Yasuda T., Yasui A., van der Horst G.T., Honma K. Circadian behavioral rhythms in Cry1/Cry2 double-deficient mice induced by methamphetamine. J. Biol. Rhythms 2008, 23:91-94.
26. Hood S., Cassidy P., Cossette M.P., Weigl Y., Verwey M., Robinson B., Stewart J., Amir S. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J. Neurosci. 2010, 30:14046-14058.
27. Iijima M., Nikaido T., Akiyama M., Moriya T., Shibata S. Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse. Eur. J. Neurosci. 2002, 16:921-929.
28. Johnson M.A., Rajan V., Miller C.E., Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 2006, 97:737-746.
29. Johnson S.A., Stout J.C., Solomon A.C., Langbehn D.R., Aylward E.H., Cruce C.B., Ross C.A., Nance M., Kayson E., Julian-Baros E., Hayden M.R., Kieburtz K., Guttman M., Oakes D., Shoulson I., Beglinger L., Duff K., Penziner E., Paulsen J.S. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007, 130:1732-1744. Predict-HD Investigators of the Huntington Study Group.
30. Kita T., Miyazaki I., Asanuma M., Takeshima M., Wagner G.C. Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. Int. Rev. Neurobiol. 2009, 88:43-64.
31. Klein D.C., Moore R.Y., Reppert S.M. Suprachiasmatic Nucleus. The Mind's Clock 1991, Oxford UP, New York.
32. Ko C.H., Takahashi J.S. Molecular components of the mammalian circadian clock. Hum. Mol. Genet. 2006, 15(Spec No 2):R271-R277.
33. Kudo T., Schroeder A., Loh D.H., Kuljis D., Jordan M.C., Roos K.P., Colwell C.S. Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp. Neurol. 2011, 228:80-90.
34. Lamont E.W., Coutu D.L., Cermakian N., Boivin D.B. Circadian rhythms and clock genes in psychotic disorders. Isr. J. Psychiatry Relat. Sci. 2010, 47:27-35.
35. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
36. Marchant E.G., Mistlberger R.E. Anticipation and entrainment to feeding time in intact and SCN-ablated C57BL/6j mice. Brain Res. 1997, 765:273-282.
37. Masubuchi S., Honma S., Abe H., Ishizaki K., Namihira M., Ikeda M., Honma K. Clock genes outside the suprachiasmatic nucleus involved in manifestation of locomotor activity rhythm in rats. Eur. J. Neurosci. 2000, 12:4206-4214.
38. Masubuchi S., Honma S., Abe H., Nakamura W., Honma K. Circadian activity rhythm in methamphetamine-treated clock mutant mice. Eur. J. Neurosci. 2001, 14:1177-1180.
39. Maywood E.S., Fraenkel E., McAllister C.J., Wood N., Reddy A.B., Hastings M.H., Morton A.J. Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding. J. Neurosci. 2010, 30:10199-10204.
40. Mehta S.H., Morgan J.C., Sethi K.D. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectr. 2008, 13:6-11.
41. Mendez M.F. Huntington's disease: update and review of neuropsychiatric aspects. Int. J. Psychiatry Med. 1994, 24:189-208.
42. Mistlberger R.E. Food-anticipatory circadian rhythms: concepts and methods. Eur. J. Neurosci. 2009, 30:1718-1729.
43. Mohawk J.A., Baer M.L., Menaker M. The methamphetamine-sensitive circadian oscillator does not employ canonical clock genes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3519-3524.
44. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005, 25:157-163.
45. Nikaido T., Akiyama M., Moriya T., Shibata S. Sensitized increase of period gene expression in the mouse caudate/putamen caused by repeated injection of methamphetamine. Mol. Pharmacol. 2001, 59:894-900.
46. Ortiz A.N., Kurth B.J., Osterhaus G.L., Johnson M.A. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 2010, 112:755-761.
47. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., Hastings M.H., Morton A.J. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:7869-7878.
48. Paulsen J.S., Zimbelman J.L., Hinton S.C., Langbehn D.R., Leveroni C.L., Benjamin M.L., Reynolds N.C., Rao S.M. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 2004, 25:1715-1721.
49. Paulsen J.S., Nehl C., Hoth K.F., Kanz J.E., Benjamin M., Conybeare R., McDowell B., Turner B. Depression and stages of Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 2005, 17:496-502.
50. Pavese N., Politis M., Tai Y.F., Barker R.A., Tabrizi S.J., Mason S.L., Brooks D.J., Piccini P. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol. Dis. 2010, 37:356-361.
51. Perez-Costas E., Melendez-Ferro M., Roberts R.C. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J. Neurochem. 2010, 113:287-302.
52. Pezuk P., Mohawk J.A., Yoshikawa T., Sellix M.T., Menaker M. Circadian organization is governed by extra-SCN pacemakers. J. Biol. Rhythms 2010, 25:432-441.
53. Politis M., Pavese N., Tai Y.F., Kiferle L., Mason S.L., Brooks D.J., Tabrizi S.J., Barker R.A., Piccini P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp. 2011, 32:258-270.
54. Reynolds G.P., Dalton C.F., Tillery C.L., Mangiarini L., Davies S.W., Bates G.P. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. J. Neurochem. 1999, 72:1773-1776.
55. Say M.J., Jones R., Scahill R.I., Dumas E.M., Coleman A., Santos R.C., Justo D., Campbell J.C., Queller S., Shores E.A., Tabrizi S.J., Stout J.C. TRACK-HD investigators. Visuomotor integration deficits precede clinical onset in Huntington's disease. Neuropsychologia 2011, 49:264-270.
56. Sedvall G., Karlsson P., Lundin A., Anvret M., Suhara T., Halldin C., Farde L. Dopamine D1 receptor number-a sensitive PET marker for early brain degeneration in Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1994, 243:249-255.
57. Shearman L.P., Sriram S., Weaver D.R., Maywood E.S., Chaves I., Zheng B., Kume K., Lee C.C., van der Horst G.T., Hastings M.H., Reppert S.M. Interacting molecular loops in the mammalian circadian clock. Science 2000, 288:1013-1019.
58. Spokes E.G. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain 1980, 103:179-210.
59. Stephan F.K., Swann J.M., Sisk C.L. Entrainment of circadian rhythms by feeding schedules in rats with suprachiasmatic lesions. Behav. Neural Biol. 1979, 25:545-554.
60. Tataroǧlu O., Davidson A.J., Benvenuto L.J., Menaker M. The methamphetamine-sensitive circadian oscillator (MASCO) in mice. J. Biol. Rhythms 2006, 21:185-194.
61. Thomas D.M., Francescutti-Verbeem D.M., Kuhn D.M. The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 2008, 105:605-616.
62. van Duijn E., Kingma E.M., van der Mast R.C. Psychopathology in verified Huntington's disease gene carriers. J. Neuropsychiatry Clin. Neurosci. 2007, 19:441-448.
63. Verwey M., Amir S. Food-entrainable circadian oscillators in the brain. Eur. J. Neurosci. 2009, 30:1650-1657.
64. Videnovic A., Leurgans S., Fan W., Jaglin J., Shannon K.M. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat. Disord. 2009, 15:471-474.
65. Waeber C., Rigo M., Chinaglia G., Probst A., Palacios J.M. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease. Synapse 1991, 8:270-280.
66. Weeks R.A., Piccini P., Harding A.E., Brooks D.J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
67. Wever R.A. The Circadian System of Man: Results of Experiment Under Temporal Isolation 1979, Springer-Verlag, New York.
68. Wiegand M., Moller A.A., Lauer C.J., Stolz S., Schreiber W., Dose M., Krieg J.C. Nocturnal sleep in Huntington's disease. J. Neurol. 1991, 238:203-208.
69. Yujnovsky I., Hirayama J., Doi M., Borrelli E., Sassone-Corsi P. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6386-6391.